WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > HGI Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industrial Impact
Serotiny | March 01, 2022
Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein engineering, and Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicines known as Gene Writing technology, today announced a collaboration to engineer programmable Gene Writer proteins. This collaboration will build on Tessera’s innovations in genome engineering technologies and apply Serotiny’s tMDP mining and design expertise to further optimize Tessera’s programmable G...
Research
Skye Bioscience, Inc. | October 13, 2021
Skye Bioscience, Inc. (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has formed a new exclusive sponsored research agreement with Emerald Health Biotechnology Espana SLU (“EHBE”), focused on developing and characterizing novel molecules that can affect the endocannabinoid system (ECS) for therapeutic benefit. The research in...
Medical
Ambagon Therapeutics | January 07, 2022
Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. Ambagon was previously seeded by RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, and Mission BioCapital. Investors from the seed round joined th...
HealthMyne | September 22, 2021
HealthMyne, a pioneer in applied radiomics, announced that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy. In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne's technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma i...
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE